Cancer I

HideShow resource information
How many people in the UK develop cancer? (1)
1 in 3
1 of 27
How many people in the UK die of cancer? (1)
1 in 5
2 of 27
Incidence of cancer in men? (4)
Prostate > Lung > Colorectal > Bladder
3 of 27
Incidence of cancer in women? (4)
Breast (Most overall) > Lung > Colorectal > Ovarian
4 of 27
Trend of cancer? (1)
incidence is increasing. Incidence and mortality are diverging.
5 of 27
Top three cancers with highest survival rates? (3)
Testicular, Malignant melanoma, Hodgkins lymphoma
6 of 27
Reasons for failure of classical chemotherapies? (3)
Toxicity to normal tissue (NTI), Life threatening, Emergence of Resistance.
7 of 27
Types of toxicity? (5)
Myelosuppression (Anaemia, Nuetropenia, Thrombocytopenia, Pancytopenia), GI, Skin and hair.
8 of 27
GI toxicity is managed with? (2)
5-HT antagonists Ondansetron and Granisetron
9 of 27
Which chemotherapies cause worst hair damage? (2)
Doxorubicin and Etoposide
10 of 27
How is this helped? (1)
Cold Cap
11 of 27
3 types of chemo resistance? (3)
Apparent - inadequate drug delivery. Inherent - cells dont have biochemical machinery to respond. Acquired - initially responsive over time resistant cells form; specific or all drugs.
12 of 27
Pancreatic cancer; life expectancy? (1)
6 month avg.
13 of 27
What is each phase of clinical trails for? (3)
Phase I - MTD and type of toxicity. Phase II - Disease specific activity. Phase III - New drug v existing therapies
14 of 27
Approaches to new drug development? (3)
Random drug screening. Target orientated development. Phenotype based development.
15 of 27
Random drug screening is done by?
National Cancer Institute
16 of 27
How many cell lines are tested?
60
17 of 27
Define GI50, TGI and LC50. (3)
GI50 - Conc. needed for 50% growth inhibition. TGI - total (100%) growth inhibition. LC50 - Lethal conc. kills 50% of cells.
18 of 27
Selection criteria for further development?
Disease Severity, COMPARE - compare fingerprint/MoA identifies new MoA, Molecular target - response compared to expression of target
19 of 27
Explain false -ve predictions using an example?
Cyclophosphamide. Pro-drug metabolised by CYP. No action in vitro as enzymes not present.
20 of 27
Hanahan and Weinberg (2000) Hallmarks of cancer? (6)
Sustaining proliferative signalling. Evading growth suppressors. Active invasion and metastasis. Enabling replicative immortality. Inducing angiogenesis. Resisting cell death.
21 of 27
2011 New hallmarks? (4)
Avoiding immune destruction. Tumour promoting inflammation. Genome instability and mutation. Deregulating cellular energetics.
22 of 27
What protein is significant in Chronic Myelogenous Leukaemia? (1)
Bcr-abl
23 of 27
Bcr-ABL? (4)
Unique to CML. Significant tyrosine kinase activity. Promotes cell proliferation > classic oncogenic driver. Imatinib targets Bcr-Abl.
24 of 27
Main mechanism of resistance? (1)
P-glycoprotein expression.
25 of 27
What is phenotype based screening? (1)
Process where compounds are identified that cause desired phenotype effect; MoA is figured out afterwards.
26 of 27
What does this allow for? (1)
Indentification of drugs with multiple MoA.
27 of 27

Other cards in this set

Card 2

Front

How many people in the UK die of cancer? (1)

Back

1 in 5

Card 3

Front

Incidence of cancer in men? (4)

Back

Preview of the front of card 3

Card 4

Front

Incidence of cancer in women? (4)

Back

Preview of the front of card 4

Card 5

Front

Trend of cancer? (1)

Back

Preview of the front of card 5
View more cards

Comments

No comments have yet been made

Similar Other resources:

See all Other resources »See all Drug Design and Development 2 resources »